The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy

References

• ChouRFanciulloGJFinePGOpioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer painJ Pain200910211313019187889
   PubMed Web of Science ®Google Scholar
• TrescotAMHelmSHansenHOpioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians’ (ASIPP) guidelinesPain Physician2008special issue 11S56218443640
   PubMed Web of Science ®Google Scholar
• GovernaleLOutpatient Prescription Opioid Utilization in the US, Years 2000–2009US Food and Drug Administration2010 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementADvisoryCommittee/UCM220950.pdfAccessed January 27, 2012
   Google Scholar
• Centers for Disease ControlNational Vital Statistics System. Unintentional Drug Poisoning in the United StatesCenters for Disease Control2010 http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdfAccessed January 27, 2012
   Google Scholar
• US Department of Health and Human ServicesSAMHSA. Office of Applied StudiesResults from the National Survey on Drug Use and Health: National Findings. Volume 1. Summary of National Findings http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf2009Accessed January 27, 2012
   Google Scholar
• KatzNPBirnbaumHGCastorAVolume of prescription opioids used nonmedically in the United StatesJ Pain Palliat Care Pharmacother201024214114420504136
   PubMedGoogle Scholar
• US General Accounting OfficePrescription Drugs, OxyContin Abuse and Diversion, and Efforts to Address the ProblemUS General Accounting Office2003 http://www.gao.gov/new.items/d04110.pdfAccessed January 27, 2012
   Google Scholar
• US Food and Drug AdministrationQuestions and answers: FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for long-acting and extended-release opioidsUS Food and Drug Administration2011 Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251752.htmAccessed January 27, 2012
   Google Scholar
• MartinsSSStorrCLZhuHChilcoatHDCorrelates of extramedical use of OxyContin versus other analgesic opioids among the US general populationDrug Alcohol Depend2009991–3586718706774
   PubMed Web of Science ®Google Scholar
• RederRFOshlackBMiottoJBBenzigerDDKaikoRFSteady-state bioavailability of controlled-release oxycodone in normal subjectsClin Ther1996181951058851456
   PubMed Web of Science ®Google Scholar
• ShramMJSathyanGKhannaSEvaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphoneJ Clin Psychopharmacol2010301253320075644
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationPost-approval REMS notification letter http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM251595.pdfAccessed January 27, 2012
   Google Scholar
• US Food and Drug AdministrationGuidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS ModificationsUS Food and Drug Administration2009 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdfAccessed January 27, 2012
   Google Scholar
• Office of National Drug Control PolicyEpidemic: responding to America’s prescription drug abuse crisis http://www.whitehousedrugpolicy.gov/publications/pdf/rx_abuse_plan.pdfAccessed January 27, 2012
   Google Scholar
• BohnertASValensteinMBairMJAssociation between opioid prescribing patterns and opioid overdose-related deathsJAMA2011305131315132121467284
   PubMed Web of Science ®Google Scholar
• DunnKMSaundersKWRutterCMOpioid prescriptions for chronic pain and overdose: a cohort studyAnn Intern Med2010152859220083827
   PubMed Web of Science ®Google Scholar
• ChabalCErjavecMKJacobsonLMarianoAChaneyEPrescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictorsClin J Pain1997131501559186022
   PubMed Web of Science ®Google Scholar
• KatzNSherburneSBeachMBehavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapyAnesth Analg2003971097110214500164
   PubMed Web of Science ®Google Scholar
• ManchikantiLPampatiVDamronKSPrevalence of opioid abuse in interventional pain medicine practice settings: a randomized clinical evaluationPain Physician20014435836516902682
   PubMedGoogle Scholar
• FishbainDAColeBLewisJRosomoffHLRosomoffRSWhat percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based reviewPain Medicine20089444445918489635
   PubMed Web of Science ®Google Scholar
• FlemingMFBalousekSLKlessigCLMundtMPBrownDDSubstance use disorders in a primary care sample receiving daily opioid therapyJ Pain20078757358217499555
   PubMed Web of Science ®Google Scholar
• FlemingMFDavisJPassikSDReported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patientsPain Medicine2008981098110618721174
   PubMed Web of Science ®Google Scholar
• BelgradeMJSchamberCDLindgrenBRThe DIRE score: predicting outcomes of opioid prescribing for chronic painJ Pain20067967168116942953
   PubMed Web of Science ®Google Scholar
• ButlerSFBudmanSHFernandezKJamisonRNValidation of a screener and opioid assessment measure for patients with chronic painPain2004112657515494186
   PubMed Web of Science ®Google Scholar
• ButlerSFFernandezKBenoitCBudmanSHJamisonRNValidation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R)J Pain20089436037218203666
   PubMed Web of Science ®Google Scholar
• Carrington ReidMEngles-HortonLWeberMUse of opioid medications for chronic noncancer pain syndromes in primary careJ Gen Intern Med20021717317911929502
   PubMed Web of Science ®Google Scholar
• WebsterLRWebsterRMPredicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk ToolPain Medicine20056643244216336480
   PubMed Web of Science ®Google Scholar
• Thalomid (thalidomide) capsules. Risk management planNDA 20-785 http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM222649.pdfAccessed January 27, 2012
   Google Scholar
• US Food and Drug AdministrationApproved risk evaluation and mitigation strategies (REMS) December 12, 2011 update. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htmAccessed January 27, 2012
   Google Scholar
• Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committeehttp://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM217510.pdfAccessed January 27, 2012
   Google Scholar
• Medication guideEXALGO (hydromorphone HCl) Extended-release tabletsHazelwood, MOMallinckrodt Inc, a Covidien company2010
   Google Scholar
• Medication guideBUTRANS CIII (buprenorphine)Stamford, CTPurdue Pharma LP2010
   Google Scholar
• Medication guideOXYCONTIN (oxycodone hydrochloride controlled-release) TabletsStamford, CTPurdue Pharma LP2010
   Google Scholar
• US Food and Drug AdministrationMedication disposal: questions and answers http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186188.htmAccessed January 27, 2012
   Google Scholar
• US Food and Drug AdministrationDisposal of unused medicines: what you should know http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htmAccessed January 27, 2012
   Google Scholar
• Medical Board of CaliforniaNew laws related to continuing medical education http://www.mbc.ca.gov/licensee/continuing_education_laws.htmlAccessed January 27, 2012
   Google Scholar
• US Food and Drug AdministrationControlled substances act. Title 21 – Food and drugs; Chapter 13 – Drug abuse prevention and control; Subchapter I – Control and enforcementPart C – Registration of manufacturers, distributors, and dispensers of controlled substances http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htmAccessed January 27, 2012
   Google Scholar
• US Food and Drug AdministrationFDA opioid REMS meeting with industryMay 16, 2011 http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm258184.htmAccessed January 27, 2012
   Google Scholar
• FinePGPortenoyRKAd Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing “best practices” for opioid rotation: conclusions of an expert panelJ Pain Symptom Manage200938341842519735902
   PubMed Web of Science ®Google Scholar